Navigation Links
BioMed Realty Trust Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:2/11/2009

SAN DIEGO, Feb. 11 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust focused on Providing Real Estate to the Life Science Industry(R), today announced financial results for the fourth quarter and full-year ended December 31, 2008.

Fourth Quarter 2008 Highlights

  • The company significantly de-leveraged during the quarter, reducing the percentage of debt to total assets to 41.8%, the company's lowest level since September 30, 2006, primarily as the result of lowering outstanding debt to $1.3 billion as of December 31, 2008 by:
    • Completing a common stock offering of 8,625,000 shares resulting in net proceeds of approximately $212.4 million
    • Repurchasing $46.8 million face value of our exchangeable senior notes for approximately $28.8 million
    • Selling a portion of the parking spaces in the garage at the Center for Life Science | Boston for approximately $28.8 million
  • Ten leasing transactions were executed representing approximately 195,000 square feet:
    • Five new leases totaling approximately 130,000 square feet, including a 36,900 square foot lease with a wholly owned subsidiary of Novo Nordisk A/S at our 530 Fairview property in Seattle, and an additional 49,286 square foot lease with Children's Hospital Corporation at the Center for Life Science | Boston
    • Five leases amended to extend their terms, totaling approximately 65,000 square feet
  • Net income available to common stockholders for the fourth quarter was $8.3 million, or $0.10 per diluted share, compared to $13.2 million, or $0.20 per diluted share, for the same period in 2007
    • This fourth quarter net income included a gain related to the repurchase of a portion of our exchangeable senior notes of $17.1 million, or $0.21 per diluted share; a charge associated with ineffectiveness of forward starting interest rate swaps of approximately $19.2 million, or $0.23 per diluted share; and a charge associated with an executive retirement of $1.1 million, or $0.01 per diluted share
    • Excluding the three items noted above, funds from operations (FFO) for the quarter would have been $38.2 million, or $0.46 per diluted share. Including these three items, FFO was $35.0 million, or $0.42 per diluted share, up from $31.6 million in the same period last year, an increase of 10.8%
  • Total revenues increased to $83.0 million, up 29.6% from $64.1 million for the same period in 2007, largely as the result of continued leasing and development deliveries
  • Same-property net operating income increased 3.7% on a cash basis from the same period in 2007

2008 Highlights

During the full year 2008, the company:

  • Completed two common stock offerings resulting in net proceeds of approximately $362.0 million
  • Repurchased $46.8 million face value of exchangeable senior notes for approximately $28.8 million
  • Acquired our 500 Fairview Avenue property, an approximately 22,000 square foot building in Seattle that is fully leased
  • Completed the purchases of the remaining minority interests in the limited liability companies that own our Waples Street property in San Diego and our 530 Fairview Avenue property in Seattle
  • Entered into a $245.0 million secured construction loan facility through our joint venture with Prudential Real Estate Investors (PREI(R)) to fund the remaining anticipated cost to complete construction at our 650 East Kendall Street property in Cambridge
  • Executed 46 leasing transactions representing approximately 848,000 square feet:
    • 28 new leases totaling approximately 527,000 square feet
    • 18 leases amended to extend their terms, totaling approximately 321,000 square feet
  • Achieved substantial completion of core and shell construction at the Center for Life Science | Boston, 530 Fairview Avenue property in Seattle, Towne Centre Drive campus in San Diego, and Landmark at Eastview campus in Tarrytown, New York, with the newly constructed buildings collectively 81.1% leased at December 31, 2008
  • Increased total revenues 13.5% for the year to $302.0 million from $266.1 million in 2007
  • Excluding the three items noted above for the fourth quarter, the company generated FFO of $139.5 million for the year, or $1.86 per diluted share, compared to $130.3 million, or $1.91 per diluted share, in 2007. Including these three items, FFO was $136.3 million, or $1.82 per diluted share
  • Continued to enhance the breadth and depth of the company's organization:
    • Added John P. Bonanno as Vice President, Development, who brings more than 18 years of experience in commercial real estate and life science business to the company
    • Promoted Kent Griffin to President and Chief Operating Officer to oversee the day-to-day operational activities and execution of the business plan while continuing to serve as the company's Chief Financial Officer
    • Promoted Jonathan P. Klassen to the position of Vice President, Legal and Secretary, and Kevin M. Simonsen to the position of Vice President, Real Estate Counsel

Commenting on BioMed's results, Alan D. Gold, BioMed's Chairman and Chief Executive Officer, said, "I am proud of our team's strong performance against the backdrop of the broader market turmoil. Our strategy of building a well-located portfolio of world-class research facilities has served us well as BioMed continues to attract top-notch life science

organizations to our tenant roster. In the fourth quarter alone, we signed leases with Children's Hospital Corporation in Boston and Novo Nordisk in Seattle, followed by our subsequent addition of Kowa Company Ltd., Japan's fifth largest trading company, at the Center for Life Science | Boston in January of this year."

Fourth Quarter and Full-Year 2008 Financial Results

Rental revenues for the fourth quarter were $63.5 million compared to $49.6 million for the same period in 2007, an increase of 27.9%. Rental revenues for 2008 were $227.5 million compared to $196.0 million in 2007, an increase of 16.1%. Same property net operating income on a cash basis for the fourth quarter was $43.7 million, an increase of 3.7% from the same period in 2007.

Total revenues for the fourth quarter were $83.0 million, compared to $64.1 million for the same period in 2007, an increase of 29.6%. For 2008, total revenues increased 13.5% to $302.0 million from $266.1 million in 2007.

Net income available to common stockholders for the fourth quarter was $8.3 million, or $0.10 per diluted share, compared to $13.2 million, or $0.20 per diluted share, for the same period in 2007. Net income available to common stockholders for 2008 was $47.9 million, or $0.67 per diluted share, compared to $55.7 million, or $0.85 per diluted share, in 2007. Annual and fourth quarter 2008 results were impacted by the following items:

  • During the fourth quarter, the company acquired $46.8 million face value of its exchangeable senior notes for approximately $28.8 million, resulting in a net gain on the extinguishment of debt of $17.1 million.
  • The company concluded that two of its forward swaps were no longer highly effective, thereby requiring the company to prospectively discontinue hedge accounting and record a loss on derivative instruments of $19.2 million for the fourth quarter.
  • The company incurred additional salary and stock compensation costs associated with an executive retirement totaling $1.1 million.

Excluding these three items, FFO for the fourth quarter would have been $38.2 million, or $0.46 per diluted share, compared to $31.6 million, or $0.46 per diluted share, in the same period last year. The increase in FFO is primarily the result of an increase in rental revenues.

FFO for 2008 increased 4.6% to $136.3 million, or $1.82 per diluted share, from $130.3 million, or $1.91 per diluted share, for full year 2007. Excluding the three items noted above, FFO for the year would have increased 8.1% over the previous year to $139.5 million, or $1.86 per diluted share. This increase is primarily the result of an increase in rental revenues due to the delivery of the Center for Life Science | Boston.

FFO is a supplemental non-GAAP financial measure used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP net income available to common stockholders to FFO and a definition of FFO are included at the end of this release.

Financing Activity

At December 31, 2008, the company's debt to total assets ratio was 41.8%.

As of December 31, 2008, the company's consolidated debt included:

  • Fixed-rate mortgage indebtedness with an aggregate outstanding principal amount of $353.2 million, including $8.8 million of debt premium, and a weighted-average effective interest rate of 5.5% at year end;
  • $250 million secured term loan, with a weighted-average effective interest rate of 3.1% at year end;
  • $128.3 million aggregate principal amount of 4.50% exchangeable senior notes due in 2026;
  • $108.8 million in outstanding borrowings under the company's $600 million unsecured revolving line of credit, with a weighted-average effective interest rate of 2.6% at year end; and
  • $507.1 million in outstanding borrowings under the company's acquisition and construction loan secured by the Center for Life Science | Boston property, with a weighted-average effective interest rate of 2.0% at year end.

During 2008, the company completed the following debt-related transactions:

  • Entered into a $245.0 million secured construction loan facility through the company's joint venture with PREI to fund the remaining anticipated cost to complete construction at its 650 East Kendall Street property in Cambridge; and
  • Completed the repurchase of $46.8 million of exchangeable senior notes at a cost of $28.8 million, or 61.6% of face value, for a gain of $17.1 million.

The company also completed the sale of 8,625,000 shares of common stock on October 6, 2008, raising net proceeds of approximately $212.4 million. The net proceeds were utilized to repay a portion of the outstanding borrowings on the company's $600 million unsecured revolving line of credit and for other general corporate and working capital purposes.

Including the October 2008 offering, the company completed two common stock offerings in 2008 resulting in net proceeds of approximately $362.0 million, which were used to repay a portion of the outstanding indebtedness under the company's $600 million unsecured revolving line of credit and for other general corporate and working capital purposes.

"We consider prudent stewardship of capital as one of our most important corporate objectives," commented Kent Griffin, President and Chief Financial Officer of BioMed. "In 2008, we continued to proactively manage our balance sheet, including having the foresight to raise common equity twice during the year and to reduce borrowing costs while increasing our debt capacity before credit began to seriously contract in the latter part of the year. As a result, we have reduced our debt level to 41.8% of total assets, our lowest level since the third quarter of 2006. We are confident that our capital structure and positioning, combined with the continued support of our shareholders and lenders, will provide us with the flexibility to capitalize on the opportunities that lie ahead."

Portfolio Update

During the quarter ended December 31 2008, the company executed ten leasing transactions representing approximately 195,000 square feet, including five new leases totaling approximately 130,000 square feet and five leases amended to extend their terms, totaling approximately 65,000 square feet.

During 2008, the company executed 46 leasing transactions representing approximately 848,000 square feet, including 28 new leases totaling approximately 527,000 square feet and 18 leases amended to extend their terms, totaling approximately 321,000 square feet.

During the quarter ended December 31, 2008, the company completed the purchase of the remaining 30% interest in the limited liability company that owns the 530 Fairview Avenue property in Seattle for approximately $2.6 million, and sold a portion of the parking spaces in the Center for Life Science | Boston garage for approximately $28.8 million.

Also in 2008, the company acquired a 22,000 square foot building at 500 Fairview Avenue in Seattle that is fully leased for an aggregate purchase price of approximately $4.0 million.

As of December 31, 2008, BioMed Realty Trust owned or had interests in 112 buildings, located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. The company's portfolio was comprised of the following, with its operating portfolio 86.9% leased to 124 tenants, as of December 31, 2008:


                                                Rentable
                                              Square Feet
                                                  -----
     Operating portfolio                        7,456,982
     Repositioning and redevelopment
      properties                                1,524,506
     Construction in progress                   1,440,867
                                                ---------
     Total portfolio                           10,422,355
                                               ----------

     Land parcels                               1,367,000
                                                ---------
     Total proforma portfolio                  11,789,355
                                               ==========



Quarterly and Annual Distributions

BioMed Realty Trust's board of directors previously declared a fourth quarter 2008 dividend of $0.335 per share of common stock, and a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from October 16, 2008 through January 15, 2009. For the full year 2008, the company declared dividends totaling $1.34 per common share and $1.84376 per Series A preferred share, with the common dividend representing an increase of 8.1% over 2007 dividend distributions.

Supplemental Information

Supplemental operating and financial data are available in the Investor Relations section of the company's web site at www.biomedrealty.com.

Teleconference and Web Cast

BioMed Realty Trust will conduct a conference call and audio web cast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) on Thursday, February 12, 2009 to discuss the company's financial results and operations for the quarter. The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at www.biomedrealty.com and www.earnings.com, or live by calling 800.299.7089 (domestic) or 617.801.9714 (international) with call ID number 80976360. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 3:00 p.m. Pacific Time on Thursday, February 12, 2009 through midnight Pacific Time on Tuesday, February 17, 2009 by calling 888.286.8010 (domestic) or 617.801.6888 (international) and using access code 78309388.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation; general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                           (Financial Tables Follow)



                           BIOMED REALTY TRUST, INC.
                          CONSOLIDATED BALANCE SHEETS
                                (In thousands)
                                  (unaudited)

                                                        December 31,
                                                      ----------------
                                                      2008        2007
                                                      ----        ----
                  ASSETS

    Investments in real estate, net                $2,957,735  $2,805,983
    Investment in unconsolidated partnerships          18,173      22,588
    Cash and cash equivalents                          21,422      13,479
    Restricted cash                                     7,877       8,867
    Accounts receivable, net                            9,417       4,457
    Accrued straight-line rents, net                   58,138      36,415
    Acquired above-market leases, net                   4,329       5,745
    Deferred leasing costs, net                       101,519     116,491
    Deferred loan costs, net                            9,933      15,567
    Other assets                                       38,256      27,676
                                                       ------      ------
      Total assets                                 $3,226,799  $3,057,268
                                                   ==========  ==========
      LIABILITIES AND STOCKHOLDERS' EQUITY

    Mortgage notes payable, net                      $353,161    $379,680
    Secured construction loan                         507,128     425,160
    Secured term loan                                 250,000     250,000
    Exchangeable senior notes                         128,250     175,000
    Unsecured line of credit                          108,767     270,947
    Security deposits                                   7,623       7,090
    Dividends and distributions payable                32,445      25,596
    Accounts payable, accrued expenses and other
     liabilities                                       66,821      74,103
    Derivative instruments                            126,091      21,768
    Acquired below-market leases, net                  17,286      23,708
                                                       ------      ------
      Total liabilities                             1,597,572   1,653,052
    Minority interests                                 12,381      17,280
    Stockholders' equity:
    Preferred stock, $.01 par value, 15,000,000
     shares authorized: 7.375% Series A cumulative
     redeemable preferred stock, $230,000,000
     liquidation preference ($25.00 per share),
     9,200,000 shares issued and outstanding at
     December 31, 2008 and 2007                       222,413     222,413
    Common stock, $.01 par value, 100,000,000
     shares authorized, 80,757,421 and 65,571,304
     shares issued and outstanding at December 31,
     2008 and 2007, respectively                          808         656
    Additional paid-in capital                      1,647,039   1,277,770
    Accumulated other comprehensive loss             (112,126)    (21,762)
    Dividends in excess of earnings                  (141,288)    (92,141)
                                                    ---------    --------
      Total stockholders' equity                    1,616,846   1,386,936
                                                    ---------   ---------
      Total liabilities and stockholders' equity   $3,226,799  $3,057,268
                                                   ==========  ==========


                              BIOMED REALTY TRUST, INC.
                         CONSOLIDATED STATEMENTS OF INCOME
                   (In thousands, except share and per share data)
                                    (unaudited)

                                 For the Three Months   For the Twelve Months
                                  Ended December 31,      Ended December 31,
                                  ------------------      ------------------
                                   2008        2007        2008        2007
                                   ----        ----        ----        ----

     Revenues:
       Rental                     $63,518     $49,645    $227,464    $195,996
       Tenant
        recoveries                 18,869      14,471      72,166      61,735
       Other income                   646         (66)      2,343       8,378
                                      ---        ----       -----       -----
         Total
          revenues                 83,033      64,050     301,973     266,109
                                   ------      ------     -------     -------
     Expenses:
       Rental
        operations                 17,255      12,006      61,600      50,789
       Real estate
        taxes                       6,181       3,816      23,129      20,353
       Depreciation
        and
        amortization               25,703      17,645      84,227      72,202
       General and
        administrative              6,406       5,880      22,834      21,870
                                    -----       -----      ------      ------
         Total
          expenses                 55,545      39,347     191,790     165,214
                                   ------      ------     -------     -------
         Income from
          operations               27,488      24,703     110,183     100,895
       Equity in
        net loss of
        unconsolidated
        partnerships                 (862)       (199)     (1,200)       (893)
       Interest
        income                        115         181         485         990
       Interest
        expense                   (11,738)     (6,641)    (39,612)    (27,654)
       Loss on
        derivative
        instruments               (19,222)          -     (19,948)          -
       Gain on extinguishment
        of debt                    17,066           -      17,066           -
                                   ------           -      ------           -
         Income from
          continuing
          operations
          before
          minority
          interests                12,847      18,044      66,974      73,338
       Minority
        interests
        in
        continuing
        operations
        of
        consolidated
        partnerships                   13          17           9         (45)
       Minority
        interests
        in
        continuing
        operations
        of operating
        partnership                  (319)       (591)     (2,086)     (2,412)
                                    -----       -----     -------     -------
       Income from
        continuing
        operations                 12,541      17,470      64,897      70,881
       Income from
        discontinued operations
        before gain
        on sale of
        assets and
        minority
        interests                       -           -           -         639
       Gain on sale
        of real
        estate
        assets                          -           -           -       1,087
       Minority
        interests
        attributable to
        discontinued operations         -           -           -         (74)
                                  -------     -------     -------        ----
         Income from
          discontinued operations       -           -           -       1,652
                                        -           -           -       -----
         Net income                12,541      17,470      64,897      72,533
       Preferred
        stock
        dividends                  (4,241)     (4,241)    (16,963)    (16,868)
                                  -------     -------    --------    --------
         Net income
          available to
          common                   $8,300     $13,229     $47,934     $55,665
          stockholders             ======     =======     =======     =======
     Income from
      continuing
      operations
      per share
      available
      to common
      stockholders:
     Basic and
      diluted
      earnings
      per share                    $0.10       $0.20       $0.67       $0.83
                                 =======       =====       =====       =====

     Net income
      per share
      available
      to common
      stockholders:
       Basic and
        diluted
        earnings
        per share                 $0.10       $0.20       $0.67       $0.85
                                  =====       =====       =====       =====

     Weighted-average common
      shares
      outstanding:
       Basic                 79,692,998  65,308,702  71,684,244  65,302,794
                             ==========  ==========  ==========  ==========
       Diluted               82,827,216  68,307,355  74,831,483  68,269,985
                             ==========  ==========  ==========  ==========






                            BIOMED REALTY TRUST, INC.
                              FUNDS FROM OPERATIONS
                (In thousands, except share and per share data)
                                  (unaudited)

    The following table provides the calculation of our FFO and a reconciliation to net income available to common stockholders (in thousands, except per share amounts):

                                  Three Months Ended     Twelve Months Ended
                                     December 31,            December 31,
                                   ----------------        ----------------
                                   2008        2007        2008        2007
                                   ----        ----        ----        ----

     Net income available to
      common stockholders         $8,300     $13,229     $47,934     $55,665
     Adjustments:
       Minority interests in
        operating partnership        319         591       2,086       2,486
       Gain on sale of real
        estate assets                  -           -           -      (1,087)
       Depreciation and
        amortization -
        unconsolidated
        partnerships                 662         394       2,100       1,139
       Depreciation and
        amortization -
        consolidated
        entities-discontinued
        operations                     -           -           -         228
       Depreciation and
        amortization -
        consolidated
        entities-continuing
        operations                25,703      17,645      84,227      72,202
       Depreciation and
        amortization -
        allocable to minority
        interest of
        consolidated joint
        ventures                     (16)       (285)        (40)       (285)
                                    ----       -----        ----       -----
     Funds from operations
      available to common
      shares and partnership
      and LTIP units             $34,968     $31,574    $136,307    $130,348
                                 =======     =======    ========    ========
     Funds from operations
      per share - diluted          $0.42       $0.46       $1.82       $1.91
                                   =====       =====       =====       =====
     Weighted-average common
      shares outstanding -
      diluted                 82,827,216  68,307,355  74,831,483  68,269,985
                              ==========  ==========  ==========  ==========



We present funds from operations, or FFO, available to common shares and partnership and LTIP units because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Foundation for Biomedical Research Announces National Distribution of Daily Radio Broadcast
2. Biomedical research center opens in Liverpool
3. Dr. Huda Zoghbi to receive 2009 Vilcek Prize in biomedical research
4. Genyous Biomed Announces Private Placement Financing
5. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
6. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
7. BioMed Realty Trusts Center for Life Science Boston Now 91% Leased
8. BioMed Realty Trust Announces Tax Treatment of 2008 Distributions
9. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
10. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
11. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
Breaking Medicine Technology: